乙炔基雌二醇与炔诺酮的混合物 | 37270-71-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 乙炔基雌二醇与炔诺酮的混合物
• 英文名称: Norethindrone and ethinyl estradiol
• 英文别名: (8R,9S,10R,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one;(8R,9S,13S,14S,17R)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
• CAS: 37270-71-6
• 化学式: C40H50O4
• 分子量: 594.8
• InChiKey: NAPPWIFDUAHTRY-XYDRQXHOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.11
• 重原子数：
  44
• 可旋转键数：
  2
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET
  申请人：FUJI CHEMICAL INDUSTRY CO., LTD.

  公开号：EP2465539A1

  公开（公告）日：2012-06-20

  There has been a need for an orally rapidly disintegrating tablet which has a good texture and taste in the oral cavity, such a sufficient hardness as not giving any worry of being chipped or dusted during production or transportation and good disintegrating properties in the oral cavity and can sustain a sufficient hardness even under humid conditions after opening. Disclosed are a disintegrating particle composition which is prepared by dispersing, in the presence of water, mannitol, xylitol, an inorganic excipient, a disintegrating agent and carmellose and drying, and an orally rapidly disintegrating tablet which comprises said disintegrating particle composition, an active substance and a disintegrating agent. The disintegrating tablet has a good texture and taste, an appropriate hardness and good disintegrating properties and can sustain a sufficient hardness under humid conditions.

  人们需要一种口服快速崩解片剂，这种片剂在口腔中具有良好的质地和口感，有足够的硬度，不会担心在生产或运输过程中碎裂或沾上灰尘，在口腔中具有良好的崩解性能，即使在开封后潮湿的条件下也能保持足够的硬度。本发明公开了一种崩解颗粒组合物，其制备方法是在有水存在的情况下，将甘露醇、木糖醇、无机赋形剂、崩解剂和卡麦芽糖分散并干燥；还公开了一种口服快速崩解片剂，其包括所述崩解颗粒组合物、活性物质和崩解剂。该崩解片具有良好的质地和口感、适当的硬度和良好的崩解性能，并能在潮湿条件下保持足够的硬度。
• USE OF FERRIC CITRATE IN PREVENTION AND/OR TREATMENT OF IRON-DEFICIENCY ANEMIA IN HYPERMENORRHEA PATIENT AND/OR PATIENT SUFFERING FROM HYPERMENORRHEA-ASSOCIATED GYNECOLOGIC DISEASE
  申请人：Japan Tobacco Inc.

  公开号：EP3685831A1

  公开（公告）日：2020-07-29

  The present invention relates to an agent for preventing and/or treating iron-deficiency anemia in patients with hypermenorrhea and/or patients with hypermenorrhea-associated gynecologic diseases. According to the present invention, an agent containing ferric citrate as an active ingredient for preventing and/or treating iron-deficiency anemia in patients with hypermenorrhea and/or patients with hypermenorrhea-associated gynecologic diseases can be provided.

  本发明涉及一种用于预防和/或治疗高月经患者和/或高月经相关妇科疾病患者缺铁性贫血的制剂。根据本发明，可以提供一种含有柠檬酸铁作为活性成分的制剂，用于预防和/或治疗高月经患者和/或高月经相关妇科疾病患者的缺铁性贫血。
• TRANSDERMAL ESTROGEN/PROGESTIN DOSAGE UNIT, SYSTEM AND PROCESS
  申请人：RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

  公开号：EP0448644A1

  公开（公告）日：1991-10-02
• EP0448644A4
  申请人：——

  公开号：EP0448644A4

  公开（公告）日：1992-01-08
• OSMOTIC, ORAL DOSAGE FORM FOR FERTILITY CONTROL
  申请人：ALZA CORPORATION

  公开号：EP0500793B1

  公开（公告）日：1993-11-03